Immune Stimulating Conjugates Patents: Who Leads, Gaps 2026
Immune Stimulating Conjugates: Patent Filing Patterns and Where the Field Is Still Open
Top 5 assignees hold 53.8% of all 411 records, and the top 10 combined reach 72.7% — concentration builds fast past the leader. Filings rose to a peak of 55 in 2021 and had fallen to 15 by 2024 — a -73% move across that span. 2025 and 2026 figures will continue to rise as publication catches up with filing, so treat the tail of the trend as incomplete rather than as evidence of a slowdown.
- 1PFIZER INC120
- 2FLAGSHIP PIONEERING INNOVATIONS V INC37
- 3ALX ONCOLOGY INC27
- 4ADJUVANCE TECHNOLOGIES INC20
- 5JUNO THERAPEUTICS INC17
See the full immune stimulating conjugates analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions on immune stimulating conjugate patents
What counts as an immune stimulating conjugate in this patent dataset?
This dataset is built from filings claiming a targeting or antibody component conjugated or co-administered with an innate-immune trigger, most commonly a TLR agonist, together with claims addressing systemic exposure control, tumor-localized release, or dose-limiting toxicity. It spans 411 published records from 2015 through the 2026 data cut-off. The search string combines conjugate and adjuvant terminology with functional claim language rather than a single chemical class, so the corpus includes both antibody-drug-conjugate-style filings and vaccine adjuvant compositions.
Who holds the most patents on immune stimulating conjugates?
One assignee leads the ranked field with 120 of the 411 records, well ahead of fifth place at 17 and tenth place at 13. The top 5 assignees combined hold 53.8% of all records, and the top 10 reach 72.7%, so ownership concentrates heavily near the top even though the ranking itself covers 91 companies. Below the top ten, filing activity spreads thinly across a long tail of single- and few-record entrants.
Is filing activity in this field growing or slowing down?
Filings peaked at 55 in 2021 and had fallen to 15 by 2024, a -73% change over that span, which reads as a genuine cooling in the years that are fully published. However, patent publication typically lags filing by around 18 months, so 2025 and 2026 figures in this dataset are still incomplete and should not be read as confirming a continued decline. 2024 is the most recent year that can be treated as a complete data point.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Immune Stimulating Conjugates covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.